<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691093</url>
  </required_header>
  <id_info>
    <org_study_id>A0221059</org_study_id>
    <nct_id>NCT00691093</nct_id>
  </id_info>
  <brief_title>Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy</brief_title>
  <official_title>Observational Study In Patients With Overactive Bladder (OAB) Treated With Toviaz® After Failure Of Previous Antimuscarinic Therapy Due To Ineffectivity Or Intolerance.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a observational study in patients treated with fesoterodine (Toviaz), who have failed
      on previous treatment for overactive bladder. It will collect epidemiological data and
      investigate the efficacy and tolerability of fesoterodine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients older than 18 years with overactive bladder after failure of previous antimuscarinic
      therapy (due to lack of efficacy or intolerance)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Micturition Frequency Per 24 Hours at Each Visit</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 or Early Termination (ET)</time_frame>
    <description>Micturition frequency: mean number of 'day time' (i.e., the time the participant was awake) micturitions per 24 hours and calculated as the total number of 'day time' urinations, divided by the total diary days collected at that visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Nocturnal Micturition Frequency Per 24 Hours at Visit 2, Visit 3, and Visit 4</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 or ET</time_frame>
    <description>Nocturnal frequency: mean number of 'night time' (the time the participant was asleep and the urge to urinate woke him/her up) micturitions and calculated as the total number of 'night time' urinations, divided by the total diary days collected at that visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Urgency Episode Frequency (UEF) Per 24 Hours at Visit 2, Visit 3, and Visit 4</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 or ET</time_frame>
    <description>UEF: mean number of micturition related urgency episodes per 24 hours and calculated as the total number of 'urgency' urinations (i.e., sudden urges to urinate and problems to delay micturition) divided by 3 (or if data for 3 days were not available, over the total number of diary days collected at that visit).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Visit 2, Visit 3, and Visit 4</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 or ET</time_frame>
    <description>The mean number of UUI episodes: total number of UUI episodes, divided by the total diary days collected at that visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Post Void Residual (PVR) Urine Volume at Visit 2, Visit 3, and Visit 4</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3 or ET</time_frame>
    <description>The PVR urine volume: measured by an ultrasound scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Evaluation of Fesoterodine</measure>
    <time_frame>Baseline, Month 3 or ET</time_frame>
    <description>The patients global evaluation of study medication was assessed via the question 'how would you rate your overall response to the study medication?' and was assessed on the four point categorical scale, ranging from 'Poor' to 'Excellent'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Evaluation of Fesoterodine</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical global evaluation of study medication was assessed via the question 'how would you rate the study medication the patient received for overactive bladder?,' and was assessed on the four point categorical scale, ranging from 'Poor' to 'Excellent.'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and Tolerability Compared to Previous Medication (Overall Treatment Effect Scale) at Visit 4</measure>
    <time_frame>Month 3 or ET</time_frame>
    <description>Overall Treatment Effect Scale: 3 questions from which a numeric score was derived. If a subject answered '(2) About the same' to question 1 then a score of 0 was given. If a subject answered '(1) Worse' to question 1, then a score between -7=a very great deal worse to -1=Almost the same, hardly worse at all was given depending on severity of their symptoms (determined from answer to question 2). If a subject answered '(3) Better' to question 1, then a score ranging from 1=Almost the same, hardly better at all to 7=A very great deal better, depending on their answer to question 3, was given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Questionnaire (OAB-q): Symptom Severity/Bother Scale</measure>
    <time_frame>Baseline, Month 3 or ET</time_frame>
    <description>Symptom severity/bother score: sub-section of the OAB-q consists of 8 questions. Each item assessed on ordinal scale (0=Not at all to 5=a very great deal). Score=sum of scores for items 1 to 8 and a further 2 points were added if subject was male. Lowest possible score=0 and highest=42. Data were transformed onto a 0 to 100 scale and analyzed based on the transformed score: Transformed Symptom Bother Score=[(Actual Total Raw Score minus Lowest possible value of raw score) divided by Range] multiplied by 100. Higher scores=greater symptom severity or bother and lower=minimal symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Scores of OAB-q at Visit 4</measure>
    <time_frame>Baseline, Month 3 or ET</time_frame>
    <description>Symptom severity/bother score: sub-section of the OAB-q consists of 8 questions. Each item assessed on ordinal scale (0=Not at all to 5=a very great deal). Score=sum of scores for items 1 to 8 and a further 2 points were added if subject was male. Lowest possible score=0 and highest=42. Data were transformed onto a 0 to 100 scale and analyzed based on the transformed score: Transformed Symptom Bother Score=[(Actual Total Raw Score minus Lowest possible value of raw score) divided by Range] multiplied by 100. Higher scores=greater symptom severity or bother and lower=minimal symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Onset Of Treatment Response</measure>
    <time_frame>Month 1, Month 2, Month 3 or ET</time_frame>
    <description>Participant's perception of treatment response assessment since the previous visit was noted at each visit. Time to onset of response was calculated in weeks from start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Doses</measure>
    <time_frame>Month 3 or ET</time_frame>
    <description>Number of subjects that changed doses throughout the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for Study Treatment Dose Changes</measure>
    <time_frame>Month 3 or ET</time_frame>
    <description>Possible change in the dose and the reasons for the change were collected and documented.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">823</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Not Specified</arm_group_label>
    <description>Not Specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fesoterodine</intervention_name>
    <description>4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment</description>
    <arm_group_label>Not Specified</arm_group_label>
    <other_name>TOVIAZ</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients older than 18 years with overactive bladder after failure of previous
        antimuscarinic therapy (due to lack of efficacy or intolerance)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  Patients with OAB after failure of previous antimuscarinic therapy - due to lack of
             efficacy: persistence of storage symptoms.

          -  Required symptoms: micturition frequency 8 and more / 24 hours and urgency episodes ≥2
             per day subjectively perceived as bothersome

          -  Due to intolerance: persistent and/or unacceptable adverse events

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to peanut or soya or any of the
             excipients.

          -  History of acute urinary retention (requiring catheterisation)

          -  Gastric retention

          -  Uncontrolled narrow angle glaucoma

          -  Myasthenia gravis

          -  Severe hepatic impairment (Child Pugh C)

          -  Concomitant use of potent CYP3A4 inhibitors in subjects with moderate to severe
             hepatic or renal impairment

          -  Severe ulcerative colitis

          -  Toxic megacolon.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>?a?a</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>AA</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Adca</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>B.Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava 2</city>
        <zip>82109</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava 2</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava 4</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava 5</city>
        <zip>85104</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava 5</city>
        <zip>85107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>851 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dolny Kubin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dunajska Streda</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hlohovec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Humenne</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koice-aca</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Komarno</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kraovsky Chlmec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liptovsky Hradok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Luenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malacky</city>
        <zip>901 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malacky</city>
        <zip>90122</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Michalovce</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Myjava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Namestovo</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nitra</city>
        <zip>951 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nové Zámky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Povaska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <zip>017 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Preov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Prievidza</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Puchov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Revuca</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ruomberok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ruzomberok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Senica</city>
        <zip>90501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Skalica</city>
        <zip>90901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sobrance</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>SpisskaNova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stropkov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Svidnik</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Topoany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trebisov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trenin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Turianske Teplice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Urany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vrable</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vranov n/Topou</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zvolen</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221059&amp;StudyName=Study%20In%20Patients%20With%20Overactive%20Bladder%20Treated%20With%20Toviaz%AE%20After%20Failure%20Of%20Previous%20Therapy</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <results_first_submitted>March 15, 2010</results_first_submitted>
  <results_first_submitted_qc>October 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2010</results_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fesoterodine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fesoterodine 4 mg or 8 mg</title>
          <description>The recommended starting dose was 4 mg once daily. Based upon individual response, the dose was increased to 8 mg once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="823"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="816"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing at Date of Cut-Off</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fesoterodine 4 mg</title>
          <description>The recommended starting dose was 4 mg once daily. Based upon individual response, the dose was increased to 8 mg once daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="823"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44-64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Micturition Frequency Per 24 Hours at Each Visit</title>
        <description>Micturition frequency: mean number of ‘day time’ (i.e., the time the participant was awake) micturitions per 24 hours and calculated as the total number of ‘day time’ urinations, divided by the total diary days collected at that visit.</description>
        <time_frame>Baseline, Month 1, Month 2, Month 3 or Early Termination (ET)</time_frame>
        <population>The full analysis set (FAS) included all patients who received at least one dose of the study medication and who had at least one post baseline efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Micturition Frequency Per 24 Hours at Each Visit</title>
          <description>Micturition frequency: mean number of ‘day time’ (i.e., the time the participant was awake) micturitions per 24 hours and calculated as the total number of ‘day time’ urinations, divided by the total diary days collected at that visit.</description>
          <population>The full analysis set (FAS) included all patients who received at least one dose of the study medication and who had at least one post baseline efficacy measurement.</population>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.661" spread="2.8565"/>
                    <measurement group_id="O2" value="10.636" spread="3.4269"/>
                    <measurement group_id="O3" value="12.664" spread="2.7612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.306" spread="1.5773"/>
                    <measurement group_id="O2" value="-2.303" spread="1.2863"/>
                    <measurement group_id="O3" value="-1.566" spread="1.4241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.482" spread="1.9022"/>
                    <measurement group_id="O2" value="-2.848" spread="1.1772"/>
                    <measurement group_id="O3" value="-3.160" spread="1.7571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 3 or ET)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.180" spread="2.1018"/>
                    <measurement group_id="O2" value="-4.000" spread="1.2293"/>
                    <measurement group_id="O3" value="-4.031" spread="1.8995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Post Void Residual (PVR) Urine Volume at Visit 2, Visit 3, and Visit 4</title>
        <description>The PVR urine volume: measured by an ultrasound scan.</description>
        <time_frame>Baseline, Month 1, Month 2, Month 3 or ET</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Post Void Residual (PVR) Urine Volume at Visit 2, Visit 3, and Visit 4</title>
          <description>The PVR urine volume: measured by an ultrasound scan.</description>
          <population>FAS</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.932" spread="27.6079"/>
                    <measurement group_id="O2" value="42.000" spread="35.6059"/>
                    <measurement group_id="O3" value="24.867" spread="27.7108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.650" spread="16.4784"/>
                    <measurement group_id="O2" value="-12.800" spread="13.2313"/>
                    <measurement group_id="O3" value="-2.364" spread="11.2500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.864" spread="20.2348"/>
                    <measurement group_id="O2" value="-18.700" spread="22.2663"/>
                    <measurement group_id="O3" value="-5.791" spread="17.8493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 3 or ET)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.800" spread="23.9575"/>
                    <measurement group_id="O2" value="-21.000" spread="24.3584"/>
                    <measurement group_id="O3" value="-7.415" spread="21.7658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Evaluation of Fesoterodine</title>
        <description>The patients global evaluation of study medication was assessed via the question 'how would you rate your overall response to the study medication?’ and was assessed on the four point categorical scale, ranging from ‘Poor’ to ‘Excellent'.</description>
        <time_frame>Baseline, Month 3 or ET</time_frame>
        <population>The safety analysis set (SAS) included all subjects who enrolled in the study, signed informed consent and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Fesoterodine 4 or 8 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Evaluation of Fesoterodine</title>
          <description>The patients global evaluation of study medication was assessed via the question 'how would you rate your overall response to the study medication?’ and was assessed on the four point categorical scale, ranging from ‘Poor’ to ‘Excellent'.</description>
          <population>The safety analysis set (SAS) included all subjects who enrolled in the study, signed informed consent and received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="823"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Evaluation of Fesoterodine</title>
        <description>Clinical global evaluation of study medication was assessed via the question ‘how would you rate the study medication the patient received for overactive bladder?,’ and was assessed on the four point categorical scale, ranging from ‘Poor’ to ‘Excellent.’</description>
        <time_frame>12 weeks</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>The recommended starting dose was 4 mg once daily. Based upon individual response, the dose was increased to 8 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Evaluation of Fesoterodine</title>
          <description>Clinical global evaluation of study medication was assessed via the question ‘how would you rate the study medication the patient received for overactive bladder?,’ and was assessed on the four point categorical scale, ranging from ‘Poor’ to ‘Excellent.’</description>
          <population>SAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="823"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy and Tolerability Compared to Previous Medication (Overall Treatment Effect Scale) at Visit 4</title>
        <description>Overall Treatment Effect Scale: 3 questions from which a numeric score was derived. If a subject answered ‘(2) About the same’ to question 1 then a score of 0 was given. If a subject answered ‘(1) Worse’ to question 1, then a score between -7=a very great deal worse to -1=Almost the same, hardly worse at all was given depending on severity of their symptoms (determined from answer to question 2). If a subject answered ‘(3) Better’ to question 1, then a score ranging from 1=Almost the same, hardly better at all to 7=A very great deal better, depending on their answer to question 3, was given.</description>
        <time_frame>Month 3 or ET</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Efficacy and Tolerability Compared to Previous Medication (Overall Treatment Effect Scale) at Visit 4</title>
          <description>Overall Treatment Effect Scale: 3 questions from which a numeric score was derived. If a subject answered ‘(2) About the same’ to question 1 then a score of 0 was given. If a subject answered ‘(1) Worse’ to question 1, then a score between -7=a very great deal worse to -1=Almost the same, hardly worse at all was given depending on severity of their symptoms (determined from answer to question 2). If a subject answered ‘(3) Better’ to question 1, then a score ranging from 1=Almost the same, hardly better at all to 7=A very great deal better, depending on their answer to question 3, was given.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.661" spread="1.1663"/>
                    <measurement group_id="O2" value="5.818" spread="0.9816"/>
                    <measurement group_id="O3" value="4.702" spread="1.7925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Questionnaire (OAB-q): Symptom Severity/Bother Scale</title>
        <description>Symptom severity/bother score: sub-section of the OAB-q consists of 8 questions. Each item assessed on ordinal scale (0=Not at all to 5=a very great deal). Score=sum of scores for items 1 to 8 and a further 2 points were added if subject was male. Lowest possible score=0 and highest=42. Data were transformed onto a 0 to 100 scale and analyzed based on the transformed score: Transformed Symptom Bother Score=[(Actual Total Raw Score minus Lowest possible value of raw score) divided by Range] multiplied by 100. Higher scores=greater symptom severity or bother and lower=minimal symptom severity.</description>
        <time_frame>Baseline, Month 3 or ET</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Questionnaire (OAB-q): Symptom Severity/Bother Scale</title>
          <description>Symptom severity/bother score: sub-section of the OAB-q consists of 8 questions. Each item assessed on ordinal scale (0=Not at all to 5=a very great deal). Score=sum of scores for items 1 to 8 and a further 2 points were added if subject was male. Lowest possible score=0 and highest=42. Data were transformed onto a 0 to 100 scale and analyzed based on the transformed score: Transformed Symptom Bother Score=[(Actual Total Raw Score minus Lowest possible value of raw score) divided by Range] multiplied by 100. Higher scores=greater symptom severity or bother and lower=minimal symptom severity.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.263" spread="17.5239"/>
                    <measurement group_id="O2" value="70.000" spread="10.1242"/>
                    <measurement group_id="O3" value="64.737" spread="17.1696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 3 or ET)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.147" spread="14.3690"/>
                    <measurement group_id="O2" value="35.682" spread="12.7520"/>
                    <measurement group_id="O3" value="32.719" spread="17.9115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Nocturnal Micturition Frequency Per 24 Hours at Visit 2, Visit 3, and Visit 4</title>
        <description>Nocturnal frequency: mean number of ‘night time’ (the time the participant was asleep and the urge to urinate woke him/her up) micturitions and calculated as the total number of ‘night time’ urinations, divided by the total diary days collected at that visit.</description>
        <time_frame>Baseline, Month 1, Month 2, Month 3 or ET</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturnal Micturition Frequency Per 24 Hours at Visit 2, Visit 3, and Visit 4</title>
          <description>Nocturnal frequency: mean number of ‘night time’ (the time the participant was asleep and the urge to urinate woke him/her up) micturitions and calculated as the total number of ‘night time’ urinations, divided by the total diary days collected at that visit.</description>
          <population>FAS</population>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.027" spread="1.2593"/>
                    <measurement group_id="O2" value="4.000" spread="1.4220"/>
                    <measurement group_id="O3" value="3.528" spread="1.3452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.104" spread="0.7960"/>
                    <measurement group_id="O2" value="-1.212" spread="0.8065"/>
                    <measurement group_id="O3" value="-0.915" spread="0.9115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.621" spread="0.9281"/>
                    <measurement group_id="O2" value="-1.848" spread="1.1290"/>
                    <measurement group_id="O3" value="-1.613" spread="1.0928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 3 or ET)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.914" spread="1.0820"/>
                    <measurement group_id="O2" value="-2.030" spread="1.3035"/>
                    <measurement group_id="O3" value="-2.072" spread="1.0907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Urgency Episode Frequency (UEF) Per 24 Hours at Visit 2, Visit 3, and Visit 4</title>
        <description>UEF: mean number of micturition related urgency episodes per 24 hours and calculated as the total number of ‘urgency’ urinations (i.e., sudden urges to urinate and problems to delay micturition) divided by 3 (or if data for 3 days were not available, over the total number of diary days collected at that visit).</description>
        <time_frame>Baseline, Month 1, Month 2, Month 3 or ET</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urgency Episode Frequency (UEF) Per 24 Hours at Visit 2, Visit 3, and Visit 4</title>
          <description>UEF: mean number of micturition related urgency episodes per 24 hours and calculated as the total number of ‘urgency’ urinations (i.e., sudden urges to urinate and problems to delay micturition) divided by 3 (or if data for 3 days were not available, over the total number of diary days collected at that visit).</description>
          <population>FAS</population>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.412" spread="2.4355"/>
                    <measurement group_id="O2" value="4.697" spread="1.9914"/>
                    <measurement group_id="O3" value="5.587" spread="3.7759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.890" spread="1.5967"/>
                    <measurement group_id="O2" value="-1.697" spread="0.9827"/>
                    <measurement group_id="O3" value="-1.650" spread="1.3065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.736" spread="1.9249"/>
                    <measurement group_id="O2" value="-2.182" spread="1.4557"/>
                    <measurement group_id="O3" value="-2.895" spread="2.6468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 3 or ET)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.127" spread="2.0210"/>
                    <measurement group_id="O2" value="-2.636" spread="1.7221"/>
                    <measurement group_id="O3" value="-3.814" spread="3.0690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Visit 2, Visit 3, and Visit 4</title>
        <description>The mean number of UUI episodes: total number of UUI episodes, divided by the total diary days collected at that visit.</description>
        <time_frame>Baseline, Month 1, Month 2, Month 3 or ET</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Visit 2, Visit 3, and Visit 4</title>
          <description>The mean number of UUI episodes: total number of UUI episodes, divided by the total diary days collected at that visit.</description>
          <population>FAS</population>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.601" spread="1.7127"/>
                    <measurement group_id="O2" value="2.933" spread="1.2551"/>
                    <measurement group_id="O3" value="3.467" spread="2.4484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Month 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.209" spread="1.0891"/>
                    <measurement group_id="O2" value="-1.067" spread="1.1738"/>
                    <measurement group_id="O3" value="-1.190" spread="1.2532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Month 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.806" spread="1.3107"/>
                    <measurement group_id="O2" value="-1.583" spread="1.4974"/>
                    <measurement group_id="O3" value="-1.781" spread="1.4729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Month 3 or ET)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.065" spread="1.4582"/>
                    <measurement group_id="O2" value="-1.733" spread="1.6836"/>
                    <measurement group_id="O3" value="-2.362" spread="1.6477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Scores of OAB-q at Visit 4</title>
        <description>Symptom severity/bother score: sub-section of the OAB-q consists of 8 questions. Each item assessed on ordinal scale (0=Not at all to 5=a very great deal). Score=sum of scores for items 1 to 8 and a further 2 points were added if subject was male. Lowest possible score=0 and highest=42. Data were transformed onto a 0 to 100 scale and analyzed based on the transformed score: Transformed Symptom Bother Score=[(Actual Total Raw Score minus Lowest possible value of raw score) divided by Range] multiplied by 100. Higher scores=greater symptom severity or bother and lower=minimal symptom severity.</description>
        <time_frame>Baseline, Month 3 or ET</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Scores of OAB-q at Visit 4</title>
          <description>Symptom severity/bother score: sub-section of the OAB-q consists of 8 questions. Each item assessed on ordinal scale (0=Not at all to 5=a very great deal). Score=sum of scores for items 1 to 8 and a further 2 points were added if subject was male. Lowest possible score=0 and highest=42. Data were transformed onto a 0 to 100 scale and analyzed based on the transformed score: Transformed Symptom Bother Score=[(Actual Total Raw Score minus Lowest possible value of raw score) divided by Range] multiplied by 100. Higher scores=greater symptom severity or bother and lower=minimal symptom severity.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.101" spread="16.0799"/>
                    <measurement group_id="O2" value="-34.318" spread="9.4928"/>
                    <measurement group_id="O3" value="-32.018" spread="17.7183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Onset Of Treatment Response</title>
        <description>Participant's perception of treatment response assessment since the previous visit was noted at each visit. Time to onset of response was calculated in weeks from start of treatment.</description>
        <time_frame>Month 1, Month 2, Month 3 or ET</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Fesoterodine 4 mg</title>
          </group>
          <group group_id="O2">
            <title>Fesoterodine 8 mg</title>
          </group>
          <group group_id="O3">
            <title>Increase of Dose From 4 mg to 8 mg Due to Lack of Efficacy</title>
          </group>
        </group_list>
        <measure>
          <title>Time To Onset Of Treatment Response</title>
          <description>Participant's perception of treatment response assessment since the previous visit was noted at each visit. Time to onset of response was calculated in weeks from start of treatment.</description>
          <population>FAS</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="754"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.27" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="3.0" spread="1.10" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O3" value="3.0" spread="2.72" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Doses</title>
        <description>Number of subjects that changed doses throughout the study period.</description>
        <time_frame>Month 3 or ET</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Fesoterodine 4 or 8 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Study Doses</title>
          <description>Number of subjects that changed doses throughout the study period.</description>
          <population>SAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="823"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed the same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluctuated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons for Study Treatment Dose Changes</title>
        <description>Possible change in the dose and the reasons for the change were collected and documented.</description>
        <time_frame>Month 3 or ET</time_frame>
        <population>SAS</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Fesoterodine 4 mg or 8 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Reasons for Study Treatment Dose Changes</title>
          <description>Possible change in the dose and the reasons for the change were collected and documented.</description>
          <population>SAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="823"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inefectivity, Not Sufficient Effectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insufficient (efficiency) effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insufficient response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor overall response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fesoterodine 4 mg or 8 mg</title>
          <description>All Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="823"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="823"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="823"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="823"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="823"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="823"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="823"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

